Items where Author is "Kang, Y"

PARK, H., URONIS, H., KANG, Y., NG, M.C.H., ENZINGER, P., LEE, K.W., RUTELLA, S., CHURCH, S.E., NORDSTROM, J., KNUTSON, K., ERSKINE, C., WU, T., YEN, J., FRANOVIC, A., MUTH, J., ROSALES, M., VADAKEKOLATHU, J., DAVIDSON-MONCADA, J., BANG, Y. and CATENACCI, D.V., 2019. Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T). Annals of Oncology, 30 (Supp5), v485. ISSN 0923-7534

RUTELLA, S., CHURCH, S.E., VADAKEKOLATHU, J., REEDER, S., SULLIVAN, A.H., WARREN, S., BAUGHMAN, J., MUTH, J., PARK, H., URONIS, H., KANG, Y., NG, M.C.H., ENZINGER, P., LEE, K.W., HUBER, K., WYNTER-HORTON, A., LI, D., BANG, Y., DAVIDSON-MONCADA, J. and CATENACCI, D.V., 2019. Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA). Annals of Oncology, 30 (Supp5), v38-v39. ISSN 0923-7534

KANG, Y., 2003. Synthesis & evaluation of some anti-proliferative substances. PhD, Nottingham Trent University.